摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3-吡啶基)苯磺酰胺 | 53472-19-8

中文名称
N-(3-吡啶基)苯磺酰胺
中文别名
——
英文名称
N-(pyridin-3-yl)benzenesulfonamide
英文别名
N-3-Pyridylbenzenesulfonamide;N-pyridin-3-ylbenzenesulfonamide
N-(3-吡啶基)苯磺酰胺化学式
CAS
53472-19-8
化学式
C11H10N2O2S
mdl
MFCD00545380
分子量
234.279
InChiKey
UFVHQLOWDFKPIU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    67.4
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:d2ba2fd3e4b8eb82094fd028486bee88
查看

反应信息

  • 作为反应物:
    描述:
    N-(3-吡啶基)苯磺酰胺 在 lithium hydroxide 、 sodium hydroxide 、 sodium hydride 、 1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 四氢呋喃甲醇N,N-二甲基甲酰胺 为溶剂, 反应 27.0h, 生成 (S)-2-({5-[(Benzenesulfonyl-pyridin-3-yl-amino)-methyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyric acid
    参考文献:
    名称:
    Second-Generation Peptidomimetic Inhibitors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo Efficacy
    摘要:
    The synthesis and evaluation of analogues of previously reported farnesyltransferase inhibitors, pyridyl benzyl ether 3 and pyridylbenzylamine 4, are described. Substitution of 3 at the 5-position of the core aryl ring resulted in inhibitors of equal or less potency against the enzyme and decreased efficacy in a cellular assay against Ras processing by the enzyme. Substitution of 4 at the benzyl nitrogen yielded 26, which showed improved efficacy and potency and yet presented a poor pharmacokinetic profile. Further modification afforded 30, which demonstrated a dramatically improved pharmacokinetic profile. Compounds 26 and 29 demonstrated significant in vivo efficacy in nude mice inoculated with MiaPaCa-2, a human pancreatic tumorderived cell line.
    DOI:
    10.1021/jm9901935
  • 作为产物:
    描述:
    苯磺酰胺3-吡啶硼酸 在 copper(II) acetate monohydrate 、 potassium carbonate 作用下, 以 为溶剂, 反应 2.0h, 以89%的产率得到N-(3-吡啶基)苯磺酰胺
    参考文献:
    名称:
    在无配体和有氧条件下,铜催化磺酰胺与硼酸在水中的 N-芳基化
    摘要:
    报道了一种在无配体条件下铜催化磺酰胺在水中芳基化的有效且新颖的方法。这种方法的显着优点是产量高、后处理程序简单和消除有毒物质。
    DOI:
    10.1055/s-0033-1340475
点击查看最新优质反应信息

文献信息

  • Sequential C–S and S–N Coupling Approach to Sulfonamides
    作者:Kai Chen、Wei Chen、Bing Han、Wanzhi Chen、Miaochang Liu、Huayue Wu
    DOI:10.1021/acs.orglett.0c00183
    日期:2020.3.6
    A one-pot three-component reaction involving nitroarenes, (hetero)arylboronic acids, and potassium pyrosulfite leading to sulfonamides was described. A broad range of sulfonamides bearing different reactive functional groups were obtained in good to excellent yields through sequential C-S and S-N coupling that does not require metal catalysts.
    描述了涉及硝基芳烃,(杂)芳基硼酸和焦亚硫酸钾的一锅三组分反应,生成磺酰胺。通过不需要金属催化剂的连续CS和SN偶联,获得了具有不同反应性官能团的多种磺酰胺,收率好至极好。
  • Sulfonamide formation from sodium sulfinates and amines or ammonia under metal-free conditions at ambient temperature
    作者:Kai Yang、Miaolin Ke、Yuanguang Lin、Qiuling Song
    DOI:10.1039/c4gc02236j
    日期:——
    A novel, practical and highly efficient method for the construction of a variety of sulfonamides mediated by I2 was demonstrated. The reaction proceeds readily at room temperature using a variety of sodium sulfinates and amines or ammonia in water in a metal-, base-, ligand-, or additive-free protocol. Primary, secondary and tertiary sulfonamides were obtained in good to excellent yields with a broad
    证明了一种新颖,实用,高效的方法来构建由I 2介导的多种磺酰胺。在室温下,使用各种亚磺酸钠和胺或水中的氨,按照无金属,无碱,无配体或无添加剂的方案,可以轻松地进行反应。伯,仲和叔磺酰胺的收率高至优异,并且具有宽泛的官能团耐受性。
  • Sulfonamidation of Aryl and Heteroaryl Halides through Photosensitized Nickel Catalysis
    作者:Taehoon Kim、Stefan J. McCarver、Chulbom Lee、David W. C. MacMillan
    DOI:10.1002/anie.201800699
    日期:2018.3.19
    highly efficient method for nickel‐catalyzed C−N bond formation between sulfonamides and aryl electrophiles. This technology provides generic access to a broad range of N‐aryl and N‐heteroaryl sulfonamide motifs, which are widely represented in drug discovery. Initial mechanistic studies suggest an energy‐transfer mechanism wherein C−N bond reductive elimination occurs from a triplet excited NiII complex
    本文中,我们报告了一种在磺酰胺和芳基亲电试剂之间形成镍催化的C-N键的高效方法。这项技术为获得广泛的N-芳基和N-杂芳基磺酰胺基序提供了通用途径,这在药物研发中得到了广泛的体现。最初的力学研究表明,一种能量转移机理是C-N键的还原消除是由三重激发的Ni II络合物引起的。还证明了在药理学相关结构合成中的后期磺酰胺化作用。
  • 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
    申请人:Djung Far-Jine Jane
    公开号:US20070293494A1
    公开(公告)日:2007-12-20
    The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.
    本发明涉及2-芳基氨基-4-(杂环)氨基嘧啶抑制剂,这些抑制剂是蛋白激酶C-alpha (PKC-α)的抑制剂,因此能够抑制PKC-α。本发明的PKC-α抑制剂对于改善心肌细胞内钙循环非常重要,从而提高心肌的收缩和舒张性能,从而减缓心力衰竭的进展。本发明还涉及包含所述2-芳基氨基-4-(杂环)氨基嘧啶的组合物以及用于控制、减轻或以其他方式减缓心力衰竭进展的方法。
  • CHEMICAL COMPOUNDS
    申请人:Pfizer Limited
    公开号:US20140315878A1
    公开(公告)日:2014-10-23
    The present invention relates to new sulfonamide URAT-1 inhibitor compounds of formula (I) or a pharmaceutically acceptable salt thereof: to compositions containing them, to processes for their preparation and to intermediates used in such processes, and to methods of treatment, wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description.
    本发明涉及新的磺胺类URAT-1抑制剂化合物的化学式(I)或其药用盐:含有它们的组合物,其制备过程以及用于这种过程的中间体,以及治疗方法,其中R1、R2、R3、R4、R5和R6如描述中所定义。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐